Acyclic nucleoside phosphonates: Past, present and future - Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: The phosphonate bridge
Acyclic nucleoside phosphonates: Past, present and future - Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: The phosphonate bridge
复制标题
DOI：
10.1016/j.bcp.2006.09.014
复制
发表时间：
2007-04-01
影响因子：
5.8
通讯作者：
De Clercq, E.
中科院分区：
文献类型：
--
作者：
De Clercq, E.
在描述S-9-（3-羟基-2-膦酰基甲氧基丙基）腺嘌呤[（S）-HPMPA]的广谱抗病毒活性20年后[De Clercq E，Holy & Rosenberg I，Sakuma T，Balzarini J，Maudgal PC.一种新型选择性广谱抗DNA病毒剂。Nature 1986; 323：464-7]，无环核苷膦酸酯已经获得了突出的治疗地位：（i）西多福韦在治疗乳头瘤病毒、疱疹病毒、腺病毒和痘病毒感染中，（ii）阿德福韦在治疗慢性肝炎B病毒（HBV）感染中，和（iii）替诺福韦林在治疗人免疫缺陷病毒（HIV）感染（AIDS）中。虽然西多福韦仅被正式批准用于治疗艾滋病患者的人巨细胞病毒（HCMV）视网膜炎，但它已成功用于治疗各种其他DNA病毒感染，特别是人乳头瘤病毒（HPV）相关病变。阿德福韦酯已成为HBV感染的标准疗法，特别是当对拉米夫定耐药时。富马酸替诺福韦酯（TDF）是三联疗法（TDF、恩曲他滨和依法韦仑）治疗艾滋病的基石，TDF单药或与恩曲他滨联合治疗可能在未来发展为B型肝炎的标准治疗。根据替诺福韦在预防猴免疫缺陷病毒的肠外、阴道内和围产期感染中所获得的结果，以及自TDF被许可用于临床使用以来，在过去5年中TDF在艾滋病患者中收集的安全性特征，应进一步追求人类HIV感染的暴露前和暴露后预防。同时，新类别的无环（即PMPO-DAPy、PMEO-DAPy、HPMPO-DAPy）和环状核苷膦酸酯（即PMDTA、PMDTT、GS 9148）已被证实具有与西多福韦、阿德福韦和/或替诺福韦相似的抗病毒效力和选择性。(c)2006年爱思唯尔公司All rights reserved.
Twenty years following the description of the broad-spectrum antiviral activity of S-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine [(S)-HPMPA] [De Clercq E, Holy & Rosenberg I, Sakuma T, Balzarini J, Maudgal PC. A novel selective broad-spectrum anti-DNA virus agent. Nature 1986;323:464-7], the acyclic nucleoside phosphonates have acquired a prominent therapeutic position: (i) cidofovir in the treatment of papilloma-, herpes-, adeno- and poxvirus infections, (ii) adefovir in the treatment of chronic hepatitis B virus (HBV) infections, and (iii) tenofovirin the treatment of human immunodeficiency virus (HIV)infections (AIDS). Although formally approved only for the treatment of human cytomegalovirus (HCMV) retinitis in AIDS patients, cidofovir has been used successfully in the treatment of various other DNA virus infections, particularly human papilloma virus (HPV)-associated lesions. Adefovir dipivoxil has become a standard therapy for HBV infections, especially when resistant to lamivudine. Tenofovir disoproxil fumarate (TDF) is the corner stone of the triple-drug (TDF, emtricitabine, and efavirenz) combination therapy for AIDS, and TDF, alone or combined with emtricitabine may in the future evolve to the standard therapy of hepatitis B. Guided by the results obtained with tenofovir in the prevention of parenteral, intravaginal and perinatal infections with simian immunodeficiency virus in monkeys, and the safety profile gathered with TDF in humans with AIDS over the past 5 years since TDF was licensed for clinical use, it should be further pursued for the pre- and post-exposure prophylaxis of HIV infections in humans. Meanwhile, new classes of both acyclic (i.e. PMPO-DAPy, PMEO-DAPy, HPMPO-DAPy) and cyclic nucleoside phosphonates (i.e. PMDTA, PMDTT, GS9148) have been accredited with an antiviral potency and selectivity similar to those of cidofovir, adefovir and/or tenofovir. (c) 2006 Elsevier Inc. All rights reserved.